A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin Alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naive Subjects who require Red Blood Cell Transfusions.
- Tiong, Ing Soo (Primary Chief Investigator (PCI))
- Kennedy, Nola (Chief Investigator (CI))
Project: Research